Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
PRAME (PReferentially expressed Antigen in Melanoma) is a gene first identified in melanoma. It has been proposed as a useful marker to differentiate melanoma from benign melanocytic neoplasms. Recently genomic testing using fluorescence hybridization has been used to aid in the diagnosis of difficult melanocytic neoplasms. We have compared PRAME staining to FISH testing results in 83 difficult to classify melanocytic neoplasms which showed spitzoid histologic features. A relatively low sensitivity of 29.6% and high specificity of 76.8% is seen with PRAME staining as compared to genomic testing with fluorescence hybridization. This study highlights the limitations of PRAME staining in spitzoid neoplasms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591151 | PMC |
| http://dx.doi.org/10.3389/fmed.2023.1265827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological features of dermal clear cell sarcoma: A series of 13 cases.
Pathol Res Pract
September 2025
Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China. Electronic address:
Background: Dermal clear cell sarcoma (DCCS) is a rare malignant mesenchymal neoplasm. Owing to the overlaps in its morphological and immunophenotypic profiles with a broad spectrum of tumors exhibiting melanocytic differentiation, it is frequently misdiagnosed as other tumor entities in clinical practice. By systematically analyzing the clinicopathological characteristics, immunophenotypic features, and molecular biological properties of DCCS, this study intends to further enhance pathologists' understanding of this disease and provide a valuable reference for its accurate diagnosis.
View Article and Find Full Text PDFGermline MC1R Variant Status and Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.
Pigment Cell Melanoma Res
September 2025
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
The melanocortin-1-receptor (MC1R) has a key role in melanocyte pigmentation regulation. Certain MC1R germline genetic variants (R alleles) result in deficient melanin production and are associated with red hair, freckling, UV sensitivity, and melanoma susceptibility. We aimed to address whether inherited polymorphisms in MC1R impact the efficacy of immune checkpoint inhibitors (ICI) in patients with metastatic melanoma.
View Article and Find Full Text PDFLarge-Scale Dermatopathology Dataset for Lesion Segmentation: Model Development and Analysis.
J Korean Med Sci
September 2025
Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Korea.
Background: With the increasing incidence of skin cancer, the workload for pathologists has surged. The diagnosis of skin samples, especially for complex lesions such as malignant melanomas and melanocytic lesions, has shown higher diagnostic variability compared to other organ samples. Consequently, artificial intelligence (AI)-based diagnostic assistance programs are increasingly needed to support dermatopathologists in achieving more consistent diagnoses.
View Article and Find Full Text PDFAnti-tumorigenic properties by trichothiodystrophy mutations in melanocytic cells.
NAR Cancer
September 2025
Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
Germline mutations in the DNA repair helicase XPD can cause the diseases xeroderma pigmentosum (XP) and trichothiodystrophy (TTD). XP patients bear an increased risk of skin cancer including melanoma. This is not observed for TTD patients despite DNA repair defects.
View Article and Find Full Text PDFPrimary intracranial malignant melanoma in a pediatric patient: A rare case report.
JAAD Case Rep
October 2025
Division of Pediatric Hematology-Oncology, Primary Children's Hospital, University of Utah, Salt Lake City, Utah.